Risk-Reducing Surgery Improves Survival Outcomes in Younger BRCA+ Breast Cancer
T-DXd Improves PFS Irrespective of Time to Progression, Type of Endocrine Resistance in HER2-Low/-Ultralow Metastatic Breast Cancer
Elacestrant Shows Tolerability in Combination With CDK4/6, PI3K Inhibitors in Advanced ER+ Breast Cancer
Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer
